151 related articles for article (PubMed ID: 32493335)
21. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Said S; Nwosu AC; Mukherjee D; Hernandez GT
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
[TBL] [Abstract][Full Text] [Related]
23. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Pratley RE
Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
[TBL] [Abstract][Full Text] [Related]
24. Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
Nozue T; Fukui K; Takamura T; Sozu T; Hibi K; Kishi S; Michishita I
J Cardiol; 2017 Mar; 69(3):518-522. PubMed ID: 27236239
[TBL] [Abstract][Full Text] [Related]
25. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
Ferreira JP; Sharma A; Mehta C; Bakris G; Rossignol P; White WB; Zannad F
Clin Res Cardiol; 2021 Jul; 110(7):1006-1019. PubMed ID: 32789678
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
27. Alogliptin benzoate for the treatment of type 2 diabetes.
Rendell M; Drincic A; Andukuri R
Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
[TBL] [Abstract][Full Text] [Related]
28. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Yabe D; Seino Y
Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
[TBL] [Abstract][Full Text] [Related]
29. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
[TBL] [Abstract][Full Text] [Related]
30. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
[TBL] [Abstract][Full Text] [Related]
31. Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry.
Inagaki N; Ueki K; Tanizawa Y; Watada H; Nakamura J; Yamada Y; Shimomura I; Nishimura R; Yamazaki T; Kadowaki T
BMJ Open; 2014 Sep; 4(9):e004760. PubMed ID: 25227623
[TBL] [Abstract][Full Text] [Related]
32. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
33. [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety].
Scheen AJ
Rev Med Liege; 2014; 69(7-8):460-6. PubMed ID: 25158388
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease.
Kato S; Fukui K; Kirigaya H; Gyotoku D; Iinuma N; Kusakawa Y; Iguchi K; Nakachi T; Iwasawa T; Kimura K
Int J Cardiol; 2016 Nov; 223():770-775. PubMed ID: 27573605
[TBL] [Abstract][Full Text] [Related]
35. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.
Noda Y; Miyoshi T; Oe H; Ohno Y; Nakamura K; Toh N; Kohno K; Morita H; Kusano K; Ito H
Cardiovasc Diabetol; 2013 Jan; 12():8. PubMed ID: 23298374
[TBL] [Abstract][Full Text] [Related]
36. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
Naik H; Czerniak R; Vakilynejad M
Br J Clin Pharmacol; 2016 Apr; 81(4):700-12. PubMed ID: 26617339
[TBL] [Abstract][Full Text] [Related]
37. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
38. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
Ferreira JP; Rossignol P; Bakris G; Mehta C; White WB; Zannad F
Cardiovasc Diabetol; 2021 Sep; 20(1):187. PubMed ID: 34521390
[TBL] [Abstract][Full Text] [Related]
39. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Hirshberg B; Katz A
Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
[TBL] [Abstract][Full Text] [Related]
40. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
White WB; Jalil F; Cushman WC; Bakris GL; Bergenstal R; Heller SR; Liu Y; Mehta C; Zannad F; Cannon CP
J Am Heart Assoc; 2018 Oct; 7(20):e009114. PubMed ID: 30371278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
